Trial Profile
A Phase IIIB Pilot Study Of Efficacy And Safety Of Anidulafungin In The Treatment Of Candidemia In Asian Patients
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 30 Apr 2021
Price :
$35
*
At a glance
- Drugs Anidulafungin (Primary)
- Indications Candidaemia
- Focus Therapeutic Use
- Sponsors Pfizer
- 23 Apr 2021 Results Results of post hoc pooled analysis from NCT00496197, NCT00548262, NCT00537329, NCT00689338, NCT00806351 and NCT00805740; evaluating patient level efficacy and safety data of anidulafungin, published in the Clinical Drug Investigation
- 17 Apr 2014 New trial record